David Golod, PhD, MBA
David Golod, PhD, MBA
Clinical Operations & Program Strategy
David Golod, PhD, MBA, has more than 26 years of biopharmaceutical industry experience spanning all phases of development across more than 10 therapeutic areas. With a unique blend of biomedical engineering and pharmaceutical business acumen, he seamlessly integrates patient needs, scientific progress, and business goals to shape clinical developmental strategies. Prior to joining Celea, David served as Vice President of Clinical Development Operations at Flex Pharma, Flexion Therapeutics, and Goldfinch Bio, and was previously Senior Director, Clinical Development Execution at Vertex Pharmaceuticals.
“What stands out about Celea is our patient-first culture and commitment to developing therapies that meet the real-world experiences and needs of people living with IPF. Our development strategy has been designed to rigorously evaluate the therapeutic strength of deupirfenidone to ensure we are delivering a truly transformative treatment option.”